High prevalence of primary antiretroviral resistance among HIV-1-infected adults and children in Bahia, a northeast state of Brazil [3]

Journal of Acquired Immune Deficiency Syndromes

Volumn 45, Issue 2, 2007, Pages 251-253

  Pedroso, Célia ^a   Queiroz, Artur T L ^b   Alcĝntara, Luis C ^b   Drexler, Jan F ^a   Diaz, Ricardo S ^c   Weyll, Neide ^d   Brites, Carlos ^a  

^a FEDERAL UNIVERSITY OF BAHIA   (Brazil)

^b INSTITUTO OSWALDO CRUZ   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

^d CREAIDS (Bahia State AIDS Referral Center)   (Brazil)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRETROVIRUS AGENT; PROTEINASE INHIBITOR; RNA DIRECTED DNA POLYMERASE INHIBITOR; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; AMINO ACID SUBSTITUTION; BRAZIL; CHILD; GENE MUTATION; GENE SEQUENCE; GENOTYPE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LETTER; PHYLOGENY; PRIORITY JOURNAL; VIRUS RESISTANCE;

ADULT; ANTI-HIV AGENTS; BRAZIL; CHILD; DRUG RESISTANCE, MULTIPLE, VIRAL; HIV INFECTIONS; HIV-1; HUMANS; PREVALENCE;

EID: 34249905472     PISSN: 15254135     EISSN: None     Source Type: Journal    
DOI: 10.1097/QAI.0b013e318050d8b0     Document Type: Letter

References (11)

1. Palella FJ Jr, Deloria-Knoll M, Chmiel JS, et al, for the HIV Outpatient Study Investigators. Survival benefit of initiating antiretroviral therapy in HIV-infected persons in different CD4+ cell strata. Ann Intern Med. 2003;138:620-626.
2. Idemyor V. Human immunodeficiency viruses and drug therapy: resistance and implications for antiretroviral therapy. AIDS Rev. 2002;4:64-82.
3. de Mendoza C, Gallego O, Soriano V. Mechanisms of resistance to antiretroviral drugs - clinical implications. Pharmacotherapy. 2002;22:659-662.
4. Boden D, Hurley A, Zhang L, et al. HIV-1 drug resistance in newly infected individuals. JAMA. 1999;282:1135-1141.
5. Bangsberg DR, Perry S, Charlebois ED, et al. Non-adherence to highly active antiretroviral therapy predicts progression to AIDS. AIDS. 2001;15:1181-1183.
6. Soares MA, Brindeiro RM, Tanuri A. Primary HIV-1 drug resistance in Brazil. AIDS. 2004;18(Suppl 3):S9-S13.
7. Brites C, Bahia F, Gilbert M, et al. Evaluation of resistance to reverse transcriptase inhibitors (RTI) in HIV-1-infected patients, before and after 6 months of single or double antiretroviral therapy. Braz J Infect Dis. 2001;5:177-182.
8. Little SJ, Holte S, Routy JP, et al. Antiretroviral-drug resistance among patients recently infected with HIV. N Engl J Med. 2002;347:385-394.
9. Ross LL, Lim ML, Liao Q, et al. Prevalence of antiretroviral drug resistance and resistance mutations in antiretroviral therapy naive HIV-infected individuals from 40 US cities during 2003. Presented at: 44th Interscience Conference on Antimicrobial Agents and Chemotherapy; 2004; Washington, DC.
10. Wrin T, Gamarnik A, Huang W, et al. Drug resistance is associated with impaired PR and RT function and reduced replication capacity: characterization of recombinant viruses derived from 200 HIV-1 infected patients [abstract 2116]. Presented at: 40th Interscience Conference on Antimicrobial Agents and Chemotherapy, Toronto, Canada, 2000.
11. Spira S, Wainberg MA, Loemba H, et al. Impact of clade diversity on HIV-1 virulence, antiretroviral drug sensitivity and drug resistance. J Antimicrob Chemother. 2003;51:229-240.